NCT02861300: A trial that was reported late by David Bajor, MD
This trial has reported, although it was 287 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02861300 |
|---|---|
| Title | Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 12, 2016 |
| Completion date | Jan. 10, 2023 |
| Required reporting date | Jan. 10, 2024, midnight |
| Actual reporting date | Oct. 23, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 287 |